Metastatic Triple-Negative Taxane-Resistant Breast Cancer: Investigating the Role of Bexarotene in Inducing Susceptibility to Chemotherapy by Differentiating Cancer Cells From a Mesenchymal-Like to an Epithelial-Like Phenotype
Latest Information Update: 10 Oct 2025
At a glance
- Drugs Bexarotene (Primary) ; Capecitabine (Primary)
- Indications Advanced breast cancer; Triple negative breast cancer
- Focus Pharmacodynamics
- Acronyms BEXMET
Most Recent Events
- 23 Sep 2025 Status changed from recruiting to completed.
- 09 Oct 2023 Planned End Date changed from 30 Jun 2023 to 30 Sep 2025.
- 09 Oct 2023 Planned primary completion date changed from 30 Jun 2023 to 30 Sep 2024.